A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases	CNS demyelinating autoimmune disease, Chronic Disease, Disease Attributes, Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, Pathologic Processes, Pathological Conditions, Signs and Symptoms, autoimmune disease, autoimmune disorder of the nervous system, chronic inflammatory demyelinating polyradiculoneuropathy, demyelinating disease, immune system disorder, multiple sclerosis, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndrome, peripheral nervous system disorder, polyneuropathy, polyradiculoneuropathy	Recruiting	Phase 1	2026-08-14		NCT07304154

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Kite, A Gilead Company	27

8 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Columbia University Irving Medical Center	New York	United States	234
Concord Repatriation General Hospital	Sydney	Australia	8
Corner Hawkesbury Road and Darcy Road	Westmead	Australia	1
Fred Hutchinson Cancer Center	Seattle	United States	250
Hoag Memorial Hospital Presbyterian	Newport Beach	United States	66
Jewish General Hospital	Montreal	Canada	15
LDS Hospital - Intermountain Health	Salt Lake City	United States	1
Stanford Neuroscience Health Center	Palo Alto	United States	15